Qiagen kept at sell by Merrill

Merrill Lynch analyst Erica Whittaker maintained Qiagen at sell after the company's second-quarter adjusted profit slightly missed Merrill's forecast, coming in 10% lower than consensus. The analyst expects second-half 2006 sales growth to accelerate to 15% to 20% year over year as a result of improved instrument sales, plus increased pull-through of sales from acquired businesses. Shares of the Venlo, The Netherlands-based biotechnology company were up 39 cents, or 2.65%, at $15.09, on volume of 468,786 shares versus the three-month running average of 368,297 shares. (Nasdaq: QGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.